Antibody-dependent cellular cytotoxicity (ADCC), also known as antibody-dependent cell-mediated cytotoxicity, is an immune mechanism wherein antibodies bind to target cells and recruit cytotoxic effector cells—such as natural killer (NK) cells, macrophages, dendritic cells, and neutrophils—to eliminate antibody-coated cells¹.

ADCC is a vital component of cell-mediated immunity that operates independently of the complement system, relying instead on innate immune responses. This mechanism is essential for recognizing and destroying infected, malignant, or otherwise abnormal cells, thereby contributing to both natural immune defense and the efficacy of antibody-based therapies.

Mechanism of ADCC

Antibodies, primarily produced by B lymphocytes, are Y-shaped molecules composed of two functional regions: the antigen-binding fragment (Fab) and the fragment crystallizable (Fc) region. The Fab region specifically binds to antigens presented on the surface of target cells, while the Fc region interacts with Fc receptors on effector cells. ADCC initiates when antibodies bind to target cell antigens, marking these cells for destruction¹.

Effector cells detect the Fc portion of these antibodies via Fc gamma receptors (FcγRs), activating the effector cells to release cytotoxic mediators¹. NK cells, the primary mediators of ADCC, release perforin and granzymes to induce apoptosis in the target cell¹. Macrophages and neutrophils contribute by producing reactive oxygen species (ROS) and hydrolytic enzymes, enhancing target cell destruction¹. Some effector cells can also induce apoptosis through Fas ligand–Fas receptor interactions. Collectively, these actions eliminate virus-infected, cancerous, and other abnormal cells tagged by antibodies.

Process of ADCC

The major steps of ADCC-mediated killing include:

Antibody binding to target cell antigens

During infections or parasitic invasions where pathogens evade phagocytosis owing to size or intracellular location, the immune system produces antibodies—predominantly IgG—to recognize pathogen-specific surface antigens³.

ADCC mediates antibody-dependent inhibition of viral replication by engaging effector cells through FcγRs that bind to the Fc region of antibodies⁴. Sequence and structure variations within the IgG molecule influence its binding affinity to FcγRs⁵, thereby modulating immune responses such as antigen clearance and effector cell activation.

The initiation of ADCC begins when the Fab or paratope region of antibodies binds to the epitope region of specific antigens expressed on the surface of target cells¹. This antibody–antigen binding effectively labels the target cell for immune-mediated destruction.

Antibodies combat viral infections by preventing viral proteins from binding to host cells, thereby blocking infection⁶. For enveloped viruses such as SARS-CoV-2, neutralizing antibodies target their spike(S) glycoprotein and inhibit its interaction with the ACE2 receptor^{7, 8}. The receptor can be found in respiratory, gastrointestinal, and endothelial cells. This disruption prevents viral entry and fusion, stopping the spread of the infection.

Recruitment and activation of effector cells

The antibodies are recognized by NK cells, macrophages, monocytes, dendritic cells, neutrophils, and eosinophils. NK cells are the primary effectors of ADCC, inducing target cell apoptosis through FcγRIIIa (CD16) recognition of IgG and subsequent signaling that leads to cytotoxic granule release⁴. It can also trigger apoptosis via death receptors such as Fas and TRAIL⁹. NK cell-derived interferon (IFN-γ) further stimulates antigen presentation and adaptive immunity¹⁰.

Although NK cells are the primary mediators, small subpopulations of antigen-experienced T lymphocytes, monocytes, and macrophages also exhibit ADCC through FcγRIIIa and TNF-α pathways^{11, 12}. Innate immune cells, such as dendritic cells, and granulocytes, such as neutrophils and eosinophils, express FcγRs¹³. Neutrophils use FcγRIIa (CD32a) to promote the killing of IgG-coated target cells by releasing inflammatory mediators and cytokines, while FcγRIIb (CD32b) negatively regulates this response¹³.

In addition, IgA binds to FcαRI (CD89) on neutrophils, promoting ADCC14, while IgE activates FcεRI on eosinophils to drive antiparasitic responses¹⁵. These diverse Fc receptor interactions enable immune cells to mediate ADCC against a range of threats.

Fc receptor binding and signal transduction

IgG engages immune cells by binding to Fc gamma receptors (FcγRs), a family of six distinct receptors in humans that mediate diverse immune functions. These receptors include FcγRI (CD64), FcγRIIa (CD32a), FcγRIIb (CD32b), FcγRIIc (CD32c), FcγRIIIa (CD16a), and FcγRIIIb (CD16b)¹⁶, and they bind to IgG subclasses with varying affinities.

Among these, FcγRI is the only high-affinity receptor¹⁶. CD64 is inducible on several myeloid cells. It can uniquely bind to IgG1 with markedly high affinity¹⁶. FcγRIIIa is the main receptor on NK cells and binds to all four IgG subclasses, with IgG1 and IgG3 exhibiting the highest affinity. CD16a is also present on macrophages and monocytes where it plays a key role in eliminating antibody-coated cells¹⁶. Antibody-coated infected cells engage Fc receptors on effector cells, triggering the initiation of degranulation.

FcγRIIb acts as the sole inhibitory receptor and it inhibits B cell maturation¹⁶. CD16b is abundant on neutrophils, but its exact function remains unclear¹⁶. FcγRIIa is broadly expressed on most leukocytes.

Effector cells release cytotoxic substances to destroy the target cell.

Upon activation, effector cells release cytotoxic molecules, including perforin and granzymes, which play essential roles in eliminating target cells. Granzymes belong to a family of serine proteases¹⁷, and they induce apoptosis. Perforin, a pore-forming protein structurally related to complement membrane attack complex (MAC) proteins, facilitates the entry of granzymes by disrupting target cell membranes¹⁸. Together, these molecules enable immune cells to destroy infected or malignant cells.

NK cells exemplify this mechanism by mediating antibody-dependent tumor cell killing through cytotoxic granule exocytosis, TNF family death receptor signaling, and the release of pro-inflammatory cytokines such as IFN-γ¹⁹. The perforin/granzyme pathway triggers apoptosis, whereas IFN-γ enhances antigen presentation and stimulates adaptive immune responses¹⁹. The predominant cytotoxic NK cell subset, CD56^dimCD16+, not only executes direct tumor cell killing but also produces IFN-γ upon activation¹⁹.

In parallel, myeloid cells such as neutrophils generate ROS via the NOX2-containing NADPH oxidase complex²⁰. These ROS contribute to microbial clearance and modulate immune responses by suppressing lymphocyte-mediated immunity, potentially preventing autoimmunity. Furthermore, extracellular ROS produced by both normal and malignant myeloid cells promotes immunosuppression in cancers²¹, including leukemia.

Target cells

ADCC targets cells displaying surface antigens recognized by antibodies, including virus-infected cells, parasites, and malignant tumor cells.

NK cells mediate ADCC by recognizing antibody-coated targets through Fc receptors. For example, NK cells detect antibodies bound to Plasmodium falciparum-infected red blood cells (iRBCs) via FcγRIIIa²², triggering degranulation and IFN-γ secretion. This response limits parasite growth and plays a key role in malaria clearance.

In cancer immunotherapy, monoclonal antibodies (mAbs) specifically bind to tumor-associated antigens, marking malignant cells for destruction by NK cells through ADCC¹⁹. This mechanism forms the basis of many immunotherapeutic strategies.

Certain tumor cells can develop resistance to ADCC by altering their surface antigen expression. Under ADCC selection pressure, some cancer cells downregulate key receptors such as epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2)²³. This phenotypic shift reduces NK cell binding and impairs ADCC-mediated killing, enabling immune evasion²³.

Factors influencing ADCC efficacy

The effectiveness of ADCC is influenced by multiple variables, including characteristics of the target cells and antibodies, as well as genetic polymorphisms in effector cells.

Target-cell characteristics

The density of antigen expression on the surface of target cells influences ADCC potency²⁴. High antigen density increases the likelihood of antibody binding and facilitates stronger immunological synapse formation between target and effector cells. Tumor cells overexpressing HER2/neu exhibit more pronounced ADCC responses following antibody treatment compared to those with lower HER2/neu levels²⁴. Nonetheless, even cells with relatively low antigen densities can be effectively targeted if the antibodies possess sufficiently high affinity for the antigen.

Furthermore, specific membrane components of target cells, such as sialic acid residues, can modulate ADCC by interacting with inhibitory receptors on effector cells. Sialic acid engagement of Siglec-7 on NK cells and Siglec-9 on neutrophils transmits suppressive signals that diminish cytotoxic function²⁵.

Antibody characteristics

Owing to structural differences in their Fc regions and varying affinities for Fcγ receptors, IgG subclasses differ in their capacity to trigger ADCC. IgG1 and IgG3 subclasses efficiently trigger FcγRIIIa-mediated ADCC, whereas IgG2 and IgG4 show limited activity. Notably, polymorphisms affecting the hinge region length in IgG3 influence its potency, with shorter hinge allotypes promoting stronger ADCC²⁶.

Modifications in Fc glycosylation profoundly affect FcγR binding affinity and subsequent effector functions²⁶. Specifically, hypergalactosylation and afucosylation increase the affinity of FcγRIIIa receptors²⁷. Afucosylation of the antibody Fc region markedly enhances ADCC by increasing FcγRIIIa binding affinity, which promotes stronger activation of NK cells and subsequent lysis of target cells. Therapeutic mAbs engineered to lack core fucose demonstrate higher ADCC efficacy against B-cell malignancies than their fucosylated counterparts²⁸.

Glycosylation patterns influence antibody pharmacokinetics; sialylated antibodies generally exhibit extended half-lives, whereas mannose-enriched variants are cleared more rapidly²⁹.

The Fc domain is critical for ADCC efficacy in various infectious diseases; for example, broadly neutralizing antibodies (bNAbs) targeting HIV-1 require intact Fc functions to engage NK cells and suppress viremia effectively³⁰. The efficiency of ADCC relies on sustained bNAb binding to the HIV-1 envelope protein, which varies due to differences in epitope exposure across viral strains and infected cells³¹. Combining potent bNAbs enhances cytolytic activity, thereby supporting their therapeutic potential in eliminating the viral reservoir in HIV-positive individuals.

Effector cell variability

Variability among effector cells, particularly NK cells, substantially impacts ADCC outcomes. Genetic, phenotypic, and environmental factors contribute to differences in NK cell activation, receptor expression, and cytokine secretion profiles, all of which impact the magnitude of ADCC responses.

A major determinant of this variability is the polymorphisms of the FcγRIIIa receptor, especially the valine (V) to phenylalanine (F) substitution at position 158. The FcγRIIIa V158 allele binds IgG1 with approximately twice the affinity of the F158 allele, resulting in enhanced NK cell-mediated ADCC³². Such polymorphisms thus affect the binding affinity of the FcγRIIIa receptor to the Fc region of IgG antibodies, thereby modulating the efficacy of mAb therapies in various cancers.

The FcγRIIIa V158F polymorphism plays a vital role in modulating cancer susceptibility and therapeutic outcomes. Individuals carrying the F158 allele have an increased risk of developing cancer³². In breast cancer patients overexpressing Erb-B2 receptor tyrosine kinase 2 (ERBB2), also known as human epidermal growth factor receptor 2 (HER2), the F/F158 and F/V158 genotypes were found in 46% and 42% of cases, respectively, whereas only 12% of patients exhibited the V/V158 genotype³². A similar distribution pattern has been reported in patients with metastatic colorectal cancer.

In contrast, the presence of the 158V allele has been associated with improved clinical responses to mAb therapies. A meta-analysis of non-Hodgkin lymphoma patients demonstrated that those with the V/V genotype showed significantly high complete response rates to rituximab-based treatments, with the effect being particularly pronounced in Asian populations.

Measuring ADCC in research and clinical settings

Evaluating the cytotoxic function of effector cells against cancer targets is essential for predicting the clinical efficacy of ADCC-dependent antibody therapies. Accurate quantification of ADCC activity informs the optimization of therapeutic antibodies and supports their development by elucidating how effectively antibodies engage immune effector cells to eliminate malignant cells.

Common techniques for assessing ADCC activity

Several in vitro techniques are employed in measuring the ADCC potency in preclinical studies.

Chromium release assay

The chromium-51 (^51Cr) release assay remains a classical method for quantifying ADCC. In this approach, target cells—often tumor cells overexpressing specific antigens such as HER2—are labeled with the radioactive isotope ^51Cr³³. Upon co-incubation with effector cells and therapeutic antibodies such as trastuzumab, antibody-coated target cells are recognized via Fc receptors on NK cells, triggering degranulation and target cell lysis. Released ^51Cr in the supernatant correlates with cytotoxic activity, providing a quantitative readout of ADCC³³.

Despite its widespread use, the ^51Cr release assay has notable limitations—it is semi-quantitative without complementary limiting dilution assays, has moderate sensitivity, may suffer from inconsistent labeling of certain cell lines, and raises safety concerns due to radioisotope use and waste management³⁴.

Flow cytometry

Flow cytometry has emerged as a sensitive and specific method to evaluate ADCC by directly detecting dead target cells. Target cells can be labeled with dyes such as carboxyfluorescein succinimidyl ester (CFSE), allowing discernment among living targets, dead cells, and effector populations³⁴. This method enables precise measurement of ADCC activity in fresh or cryopreserved peripheral blood mononuclear cells (PBMCs) and offers enhanced reproducibility compared to radioactive assays. Flow cytometry assays are increasingly considered the gold standard for ADCC assessment in both research and clinical contexts.

Importance of ADCC assays in drug development and quality control

IgG1 mAbs, such as cetuximab and necitumumab, induce ADCC, enhancing tumor immunogenicity and supporting their combination with immunotherapies³⁵.

While cetuximab has been extensively studied, research on necitumumab remains limited, though both show similar cytotoxicity against certain colorectal cancer cell lines.

Panitumumab, an IgG2 mAb, has comparable anti-EGFR activity to cetuximab but differs in epitope binding³⁵. Studies show its non-inferiority in metastatic colorectal cancer treatments. However, in head and neck squamous cell carcinoma, panitumumab has not demonstrated significant clinical benefits. In contrast, cetuximab has been approved due to its strong efficacy, potentially due to differences in the IgG backbone.

Biomarkers and standardization

mAbs targeting tumor-associated antigens are used to treat various cancers through mechanisms such as signaling inhibition and ligand blocking. ADCC plays a key role in its effectiveness. Various strategies have been developed to enhance ADCC activity with the biomarkers in clinical treatments.

Emerging biomarkers to track ADCC efficiency

• CD20, found only on B cells, is an ideal target for mAb therapy in B-cell malignancies. For example, rituximab, commonly used with chemotherapy, inhibits tumor growth by binding to CD20³⁶. It also activates complement-dependent cytotoxicity (CDC) and ADCC through macrophages and NK cells.
• EGFR, a membrane protein tyrosine kinase, is overexpressed in various cancers³⁷, including head and neck, prostate, colon, and breast cancer. For example, cetuximab, an anti-EGFR antibody, inhibits growth factor binding, disrupting signaling pathways and leading to cell cycle arrest, apoptosis, and reduced angiogenesis³⁸. Additionally, cetuximab enhances antitumor activity by inducing ADCC.
• HER2, a member of the epidermal growth factor receptor family, is an oncogene overexpressed in certain malignancies such as ovarian and breast cancers. For example, trastuzumab, the first mAb targeting HER2, is a humanized IgG1 used in cancer therapy³⁸. It exerts its antitumor effects by inducing ADCC in vivo.
• GD2 is a surface lipid overexpressed in melanoma and neuroblastoma, making it a suitable target for ADCC-inducing mAbs. For example, dinutuximab is the first mAb targeting GD2 to receive approval for treating high-risk neuroblastoma in children³⁸.
• CD38 is a surface glycoprotein highly overexpressed in multiple myeloma cells but present at low levels in normal tissues. Daratumumab, a fully human IgG1 mAb, is approved for treating refractory multiple myeloma in combination with lenalidomide and dexamethasone³⁸. Preclinical studies show that daratumumab induces ADCC against multiple myeloma cell lines and patient-derived cancer cells.

Need for standardized protocols in research and clinical settings

Measuring Fc effector function in ADCC for therapeutic antibodies has been challenging due to inconsistencies in primary cell-based methods and complex assay procedures³⁹. Thus, standardized protocols and biological assays are essential to improve the efficiency of ADCC in research and clinical settings.

For example, the ADCC reporter bioassay is a bioluminescent assay that quantifies antibody activity through FcγRIIIa-mediated pathway activation³⁹. It uses engineered Jurkat cells expressing FcγRIIIa variants and a nuclear factor of activated T Cells (NFAT)-driven firefly luciferase, which is activated when the antibody binds to target cell antigens and FcγRIIIa receptors³⁹.

The luciferase activity induced by the antibody in effector cells is assessed through luminescence, offering a precise measurement for antibody and antigen-presenting target cells. This assay is useful for evaluating antibody glycosylation effects in early drug development and meets the precision and accuracy standards for potency and stability testing³⁹. It follows a simple add-mix-read assay format, with vital parameters such as the effector-to-target ratio and incubation times requiring optimization based on the specific antibody and target cell pair.

ADCC versus other immune mechanisms

As discussed before, IgG antibodies exert antitumor effects both directly—by initiating cell death pathways and blocking critical receptor functions—and indirectly through Fc-mediated effector mechanisms. These include ADCC, antibody-dependent cellular phagocytosis (ADCP), and CDC, each playing essential roles in antibody-based cancer therapeutics.

ADCC versus complement-dependent cytotoxicity

Table 1: Comparison of complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity

ADCC versus antibody-dependent cellular phagocytosis

Table 2: Comparison of antibody-dependent cellular phagocytosis and antibody-dependent cellular cytotoxicity

Challenges and future directions for ADCC research

ADCC exploits innate immune cells, chiefly NK cells, to mount antitumor responses by targeting antibody-coated cells. Enhancing NK cell function through mAbs and immunotherapeutic agents remains a central strategy to boost ADCC efficacy in oncology. Nonetheless, several challenges impede the consistent success of ADCC-based therapies.

Current challenges

• Targeted therapies reshape the tumor microenvironment but face immune evasion for ADCC response. Many cancers suppress immunity, leading to impaired responses. Immunotherapy aims to restore immunity but has low response rates⁴¹, while targeted therapies show higher initial success but often develop resistance.
• Combining these approaches shows promise for improved clinical effectiveness across more patients. However, the success of such combinations depends on the tumor type and its immune microenvironment. For example, healthy cells express MHC class I antigens for immune recognition, but tumor cells often downregulate MHC-I to evade T-cell detection. This limits the effectiveness of T cell-based immunotherapies, as T cells struggle to recognize MHC-I negative (MHC-I^neg) tumors⁴¹. However, NK cells can overcome this challenge by targeting tumors regardless of MHC status and without requiring neoantigen presentation.
• Multiple factors, including antigen expression, antibody affinity, effector cell interactions, and patient-specific immune responses, influence the efficacy of therapeutic antibodies for ADCC response. This variability significantly affects clinical outcomes in antibody-based therapies, such as cancer immunotherapy and autoimmune disease treatments. Understanding these variations is vital to optimizing therapeutic strategies and improving patient responses.
• Although PBMC and NK cells are commonly used for ADCC quantification, donor variability in FcγR genotypes causes inconsistencies. To address this, engineered NK cell lines with high-affinity CD16V and single-use effector cell lines have been developed for standardized assays¹. A robust, clinically applicable ADCC assay using patient blood samples without NK cell isolation is important for predicting responses and comparing newly designed mAbs.
• Other challenges include distinguishing direct mAb effects from ADCC responses in clinical settings. Optimizing NK cell activation can provide stronger antitumor activity.

Future advancements in ADCC therapies

The Fc region of IgG-based bispecific antibodies (bsAbs) can be modified to balance Fc functionality, either mitigating adverse effects or enhancing antitumor activity⁴². One approach to reducing ADCC effects involves selecting IgG subclasses such as IgG2 or IgG4, which have lower FcγR binding, or introducing Fc silent mutations to prevent nonspecific immune activation⁴². Conversely, optimizing Fc interactions with FcγRs, such as FcγRIIIa on NK cells, can enhance ADCC and promote antitumor responses, a strategy used in mAbs such as trastuzumab and bsAbs such as amivantamab⁴².

Removal or reduction of core fucose in Fc N-glycans markedly increases IgG1 binding affinity to FcγRIIIa, bolstering NK cell activation and expanding the therapeutic potential of bsAbs targeting oncogenic pathways⁴².

Some mAbs targeting inhibitory checkpoints on T cells, such as anti-PD-1, are engineered to avoid ADCC to prevent immune cell depletion. In contrast, newer anti-PD-L1 antibodies combine checkpoint blockade with ADCC enhancement to improve antitumor efficacy¹.

Conclusion

ADCC represents a crucial immune effector mechanism whereby antibodies guide NK cells and other immune effectors to identify and eliminate antibody-coated targets, including infected or malignant cells. This process is fundamental to immune surveillance and underpins the effectiveness of many mAb therapies in oncology.

Despite its therapeutic promise, ADCC efficacy is influenced by tumor immune evasion, antigen heterogeneity, Fc receptor polymorphisms, and patient immune variability. Ongoing research focuses on Fc engineering, glycoengineering, and bispecific antibody design to enhance ADCC activity and clinical outcomes in cancer immunotherapy.

FAQs

How do NK cells contribute to ADCC?

NK cells play a key role in ADCC by recognizing antibody-coated target cells through their FcγRIIIa (CD16) receptors. Upon engagement of CD16 with the antibody-coated target cell, the NK cell becomes activated and releases cytotoxic granules containing perforin and granzymes. These molecules work together to induce apoptosis, or programmed cell death, in the target cell. Through this mechanism, NK cells play a vital role in bridging the adaptive immune system with innate effector functions, enhancing the immune system’s ability to eliminate harmful cells. Additionally, NK cells secrete cytokines such as IFN-γ to enhance immune responses and promote antigen presentation.

What role do antibodies play in ADCC?

Antibodies, primarily immunoglobulin G, bind to antigens on target cells, marking them for destruction by immune effector cells. The Fc region of these antibodies interacts with Fc receptors on NK cells and other immune cells, triggering cytotoxic responses. This leads to the release of perforin and granzymes, which induce apoptosis in the target cells. Thus, antibodies mark the target cell for destruction and facilitate its recognition and elimination by immune cells, making them essential mediators of ADCC.

References

1. Zahavi, D., AlDeghaither, D., O’Connell, A., et al. Enhancing antibody-dependent cell-mediated cytotoxicity: A strategy for improving antibody-based immunotherapy. Antibody therapeutics. 1(1), 7–12 (2018).
2. Lo Nigro, C., Macagno, M., Sangiolo, D., et al. NK-mediated antibody-dependent cell-mediated cytotoxicity in solid tumors: Biological evidence and clinical perspectives.  Annals of translational medicine.  7(5), 105 (2019).
3. Marshall, J.S., Warrington, R., Watson, W.  et al.  An introduction to immunology and immunopathology. Allergy, asthma & clinical Immunology. 14 (Suppl 2), 49 (2018).
4. van Erp, E. A., Luytjes, W., Ferwerda, G., et al. Fc-mediated antibody effector functions during respiratory syncytial virus infection and disease.  Frontiers in immunology.  10, 548 (2019).
5. Damelang, T., Brinkhaus, M., van Osch, T. L. J., et al. Impact of structural modifications of IgG antibodies on effector functions. Frontiers in immunology. 14, 1304365 (2024).
6. Murin, C. D., Wilson, I. A., & Ward, A. B. Antibody responses to viral infections: A structural perspective across three different enveloped viruses. Nature microbiology. 4(5), 734–747 (2019).
7. de Alwis, R., Chen, S., Gan, E. S., et al. Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development. EBioMedicine. 55, 102768 (2020).
8. Xiaojie, S., Yu, L., Lei, Y., Guang, Y., & Min, Q. Neutralizing antibodies targeting SARS-CoV-2 spike protein.  Stem cell research.  50, 102125 (2020).
9. Prager, I., & Watzl, C. Mechanisms of natural killer cell-mediated cellular cytotoxicity. Journal of leukocyte biology. 105(6), 1319–1329 (2019).
10. Alspach, E., Lussier, D. M., & Schreiber, R. D. Interferon γ and its important roles in promoting and inhibiting spontaneous and therapeutic cancer immunity.  Cold spring harbor perspectives in biology.  11(3), a028480 (2019).
11. Yeap, W., Wong, K., Shimasaki, N.  et al.  CD16 is indispensable for antibody-dependent cellular cytotoxicity by human monocytes.  Scientific reports.  6, 34310 (2016).
12. Taylor R. P. T cells reinforce NK cell-mediated ADCC. Blood. 143(18), 1786–1787 (2024).
13. Sepúlveda-Delgado, J., Llorente, L., & Hernández-Doño, S. A comprehensive review of Fc gamma receptors and their role in systemic lupus erythematosus. International journal of molecular sciences. 26(5), 1851 (2025).
14. Borrok, M. J., Luheshi, N. M., Beyaz, N., et al. Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding.  mAbs.  7(4), 743–751 (2015).
15. Mukai, K., Tsai, M., Starkl, P., et al. IgE and mast cells in host defense against parasites and venoms.  Seminars in immunopathology.  38(5), 581–603 (2016).
16. Barb A. W. Fc γ receptor compositional heterogeneity: Considerations for immunotherapy development. The journal of biological chemistry. 296, 100057 (2021).
17. Matsubara, J. A., Tian, Y., Cui, J. Z., et al. Retinal distribution and extracellular activity of granzyme B: A serine protease that degrades retinal pigment epithelial tight junctions and extracellular matrix proteins. Frontiers in immunology. 11, 574 (2020).
18. Kulma, M., & Anderluh, G. Beyond pore formation: Reorganization of the plasma membrane induced by pore-forming proteins. Cellular and molecular life sciences: CMLS. 78(17-18), 6229–6249 (2021).
19. Wang, W., Erbe, A. K., Hank, J. A., et al. NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy. Frontiers in immunology. 6, 368 (2015).
20. Nguyen, G. T., Green, E. R., & Mecsas, J. Neutrophils to the ROScue: Mechanisms of NADPH oxidase activation and bacterial resistance.  Frontiers in cellular and infection microbiology.  7, 373 (2017).
21. Aboelella, N. S., Brandle, C., Kim, T., et al. Oxidative stress in the tumor microenvironment and its relevance to cancer immunotherapy. Cancers. 13(5), 986 (2021).
22. Sekar, P., Rajagopalan, S., Shabani, E., et al. NK cell-induced damage to P. falciparum-infected erythrocytes requires ligand-specific recognition and releases parasitophorous vacuoles that are phagocytosed by monocytes in the presence of immune IgG.  PLoS pathogens.  19(11), e1011585 (2023).
23. Zahavi, D. J., Erbe, R., Zhang, Y. W., et al. Antibody dependent cell-mediated cytotoxicity selection pressure induces diverse mechanisms of resistance. Cancer biology & therapy. 24(1), 2269637 (2023).
24. Temming, A. R., de Taeye, S. W., de Graaf, E. L., et al. Functional attributes of antibodies, effector cells, and target cells affecting NK cell-mediated antibody-dependent cellular cytotoxicity.  Journal of immunology.  203(12), 3126–3135 (2019).
25. Chan, C., Lustig, M., Jansen, J. H. M., et al. Sialic acids on tumor cells modulate IgA therapy by neutrophils via inhibitory receptors Siglec-7 and Siglec-9. Cancers. 15(13), 3405 (2023).
26. de Taeye, S. W., Bentlage, A. E. H., Mebius, M. M., et al. FcγR binding and ADCC activity of human IgG allotypes.  Frontiers in immunology.  11, 740 (2020).
27. Thomann, M., Reckermann, K., Reusch, D., et al. Fc-galactosylation modulates antibody-dependent cellular cytotoxicity of therapeutic antibodies. Molecular immunology. 73, 69–75 (2016).
28. Pereira, N. A., Chan, K. F., Lin, P. C., & Song, Z. The “less-is-more” in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity. mAbs. 10(5), 693–711 (2018).
29. Zhou, X., Motta, F., Selmi, C., et al. Antibody glycosylation in autoimmune diseases. Autoimmunity reviews. 20(5), 102804 (2021).
30. Danesh, A., Ren, Y., & Brad Jones, R. (2020). Roles of fragment crystallizable-mediated effector functions in broadly neutralizing antibody activity against HIV. Current opinion in HIV and AIDS. 15(5), 316–323 (2020).
31. Bruel, T., Guivel-Benhassine, F., Amraoui, S., et al. Elimination of HIV-1-infected cells by broadly neutralizing antibodies. Nature communications. 7, 10844 (2016).
32. Kim, J., Lee, J. Y., Kim, H. G., et al. Fc receptor variants and disease: A crucial factor to consider in the antibody therapeutics in clinic. International journal of molecular sciences. 22(17), 9489 (2021).
33. van der Haar Àvila, I., Marmol, P., Kiessling, R., et al. Evaluating antibody-dependent cell-mediated cytotoxicity by chromium release assay.  Methods in molecular biology.  1913, 167–179 (2019).
34. Yamashita, M., Kitano, S., Aikawa, H.  et al.  A novel method for evaluating antibody-dependent cell-mediated cytotoxicity by flowcytometry using cryopreserved human peripheral blood mononuclear cells.  Scientific reports.  6, 19772 (2016).
35. Baysal, H., De Pauw, I., Zaryouh, H., et al. The right partner in crime: Unlocking the potential of the anti-EGFR antibody cetuximab  via  combination with natural killer cell chartering immunotherapeutic strategies. Frontiers in immunology. 12, 737311 (2021).
36. Klein, C., Jamois, C., & Nielsen, T. Anti-CD20 treatment for B-cell malignancies: current status and future directions. Expert opinion on biological therapy. 21(2), 161–181 (2021).
37. Hsu, J. L., & Hung, M. C. The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer.  Cancer metastasis reviews.  35(4), 575–588 (2016).
38. Ochoa, M. C., Minute, L., Rodriguez, I., et al. Antibody-dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells. Immunology and cell biology. 95(4), 347–355 (2017).
39. Garvin, D., Stecha, P., Gilden, J., et al. Determining ADCC activity of antibody-based therapeutic molecules using two bioluminescent reporter-based bioassays. Current protocols. 1(11), e296 (2021).
40. van der Horst, H. J., Nijhof, I. S., Mutis, T., et al. Fc-engineered antibodies with enhanced Fc-effector function for the treatment of B-cell malignancies. Cancers. 12(10), 3041 (2020).
41. Baysal, H., De Pauw, I., Zaryouh, H., et al. The right partner in crime: Unlocking the potential of the anti-EGFR antibody cetuximab  via  combination with natural killer cell chartering immunotherapeutic strategies.  Frontiers in immunology.  12, 737311 (2021).
42. Herrera, M., Pretelli, G., Desai, J., et al. Bispecific antibodies: advancing precision oncology. Trends in cancer. 10(10), 893–919 (2024).